AMHERST, Mass. – This fall’s Graduate School class at the University of Massachusetts Amherst has an increased number of international students, a slightly higher overall number enrolled than last year, and reflects more selectivity in choosing who will pursue graduate degrees, university officials say.
The incoming class includes 1,586 students, up from 1,540 in the fall of 2011. Overall, the Graduate School has about 6,300 students pursuing advanced degrees, including those enrolled in online programs.
John McCarthy is vice provost for graduate education and dean of the Graduate School.
AMHERST, Mass. – Carl Caspersen, an expert in physical activity and diabetes at the Centers for Disease Control and Prevention (CDC), Atlanta, will be the keynote speaker at a public diabetes prevention and management seminar and panel discussion at the University of Massachusetts Amherst’s Marriott Center on Monday, Oct. 22 from 3 to 5 p.m. A reception will follow.
Poster-sized pages of the new bilingual children’s book, “Henry Gets Moving,” published this week by University of Massachusetts Amherst athletic team physician Dr. Pierre Rouzier, will be presented at a “Story Walk” for parents and children as part of Holyoke’s Envision Depot Square block party beginning at 4 p.m. on Saturday, Oct. 13.
AMHERST, Mass. – University of Massachusetts Amherst neuroscientist Luke Remage-Healey will receive the 2012 Frank A. Beach Award from the Society for Behavioral Neuroendocrinology for work showing exceptional promise and significant contributions in the field of behavioral neuroendocrinology. Named after a founder of the field, the award will be presented during the society’s annual meeting this week in New Orleans. Remage-Healey will also give a lecture at the society’s annual meeting next year.
AMHERST, Mass. – University of Massachusetts Amherst researchers, experts in revealing molecular structure by X-ray crystallography, have identified two new small “chaperone” molecules that may be useful in treating the inherited metabolic disorder known as Schindler/Kanzaki disease. This offers hope for developing the first ever drug treatment for this very rare disease. 
AMHERST, Mass. – Until recently, medical researchers had little hope of experimentally manipulating naïve T cells to study their crucial roles in immune function, because they were largely impenetrable, says polymer scientist Gregory Tew of the University of Massachusetts Amherst: “So far off limits we could not readily get inside to investigate their workings.”